Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Articles

Page Path
HOME > J Korean Cancer Assoc > Accepted articles > Article
Original Article
Stage Evaluation of Cystic Duct Cancer
Yeseul Kim1orcid , You-Na Sung1orcid , Haesung Jung2, Kyung Jin Lee3, Daegwang Yoo4, Sun-Young Jun5, HyungJun Cho2, Shin Hwang6, Woohyung Lee7orcid , Seung-Mo Hong8orcid

DOI: https://doi.org/10.4143/crt.2024.660 [Accepted]
Published online: September 19, 2024
1Department of Pathology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea
2Department of Statistics, Korea University, Seoul, Korea
3Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
4Department of Surgery, Seoul Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Seoul, Korea
5Department of Pathology, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea
6Division of Liver Transplantation and Hepatobiliary Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
7Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
8Department of Pathology, Brain Korea 21 Project, Asan Medical Center, Ulsan University College of Medicine, Seoul, Korea

This work was presented in part at the 112th annual meeting of the United States and Canadian Academy of Pathology on March 11~16, 2023, in New Orleans, LA, USA
Corresponding author:  Woohyung Lee
Tel: 82-2-3010-3933 Email: ywhnet@gmail.com
Seung-Mo Hong
Tel: 82-2-3010-4558 Fax: 82-2-472-7898 Email: smhong28@gmail.com
Yeseul Kim and You-Na Sung contributed equally to this study as co-first authors.
Received: 16 July 2024   • Accepted: 15 September 2024
  • 242 Views
  • 24 Download
  • 0 Crossref
  • 0 Scopus

Purpose
Cystic duct cancers (CDCs) have been classified as extrahepatic bile duct cancers or gallbladder cancers (GBCs); however, it is unclear whether their clinical behavior is similar to that of distal extrahepatic bile duct cancers (DBDCs) or GBCs.
Materials and Methods
T category of the CDCs was classified using current T category scheme of the GBCs and DBDCs, and clinicopathological factors were compared among 38 CDCs, 345 GBCs, and 349 DBDCs. We modified Nakata’s classifications (type 1, confined within cystic duct (CD); combined types 2–4, extension beyond CD) and compared them.
Results
No significant overall survival (OS) difference was observed between the patients with CDC, GBC, and DBDC. The T category of GBC staging was more accurate at distinguishing OS in patients with CDC than the DBDC staging. Patients with T3 CDC and GBC showed a significant OS difference when using the T category for GBC staging, while those with T1–T2 CDC and GBC showed no significant difference. In contrast, the T category of DBDC staging did not show any significant OS difference between patients with T1–T2 CDC and DBDC or T3 CDC and DBDC. Patients with type 1 CDC had significantly better OS than those with combined types.
Conclusion
Unlike GBCs and DBDCs, CDCs exhibit distinct clinicopathological characteristics. The OS is better when the CDC confines within the CD, compared to when it extends beyond it. Therefore, we propose a new T category scheme (T1, confined to CD; T2, invaded beyond CD) for better classifying CDCs.


Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP